Saredutant

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Template:Short description Template:Drugbox

Saredutant (SR-48,968) is a drug that acts as a NK2 receptor antagonist.[1] It was under development by Sanofi-Aventis as a novel antidepressant and anxiolytic and made it to phase III clinical trials. However, in May 2009, Sanofi-Aventis published its quarterly results and announced the cessation of 14 research/development projects, among which was saredutant for the treatment of major depressive disorder.[2]

See also

References

<templatestyles src="Reflist/styles.css" />

  1. Script error: No such module "Citation/CS1".
  2. Script error: No such module "citation/CS1".

Script error: No such module "Check for unknown parameters".

Script error: No such module "Navbox". Script error: No such module "navbox". Template:Neurokinin receptor modulators Template:Anxiolytic-stub